{
    "clinical_study": {
        "@rank": "87309", 
        "arm_group": [
            {
                "arm_group_label": "WX-037", 
                "arm_group_type": "Experimental", 
                "description": "PI3K inhibitor"
            }, 
            {
                "arm_group_label": "WX-037 in combination with WX-554", 
                "arm_group_type": "Experimental", 
                "description": "PI3K inhibitor in combination with MEK inhibitor"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the safety of escalating doses of the novel PI3K\n      inhibitor WX-037 and to explore its effectiveness in combination with WX-554 which targets\n      mitogen activated protein kinase (MEK1 and MEK2). Preclinical evidence indicates that these\n      two novel compounds could provide targeted inhibition of both pathways to block tumour\n      growth."
        }, 
        "brief_title": "Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Advanced Solid Tumours", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with advanced, metastatic and/or progressive solid tumors for whom there is\n             no effective standard therapy available (for part 2 in addition patients for whom\n             their PI3K pathway is deregulated)\n\n          -  Evaluable or measurable disease\n\n          -  Has normal organ function; is no greater than 2 on the ECOG performance scale\n\n          -  Negative hCG test in women of childbearing potential\n\n        Exclusion Criteria:\n\n          -  History of diabetes requiring daily medication or history of grade 3 or more fasting\n             hyperglycemia\n\n          -  Patients with major surgery, radiotherapy, or immunotherapy within 4 weeks of\n             starting the study\n\n          -  Clinical significant, unresolved toxicity from previous anti-cancer therapy\n\n          -  Patients who previously received a MEK inhibitor (for combination part only)\n\n          -  Presence of active gastrointestinal disease or other condition that will interfere\n             significantly with the absorption, distribution, metabolism, or excretion of drugs\n\n          -  Known medical history of retinal vein occlusion, intraocular pressure greater than 21\n             mm Hg or patient considered at risk of retinal vein thrombosis (combination part\n             only)\n\n          -  Known HIV positivity or active hepatitis B or C infection\n\n          -  History of clinically significant cardiac condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01859351", 
            "org_study_id": "WX/90-001", 
            "secondary_id": "2012-004552-11"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "WX-037", 
                    "WX-037 in combination with WX-554"
                ], 
                "intervention_name": "WX-037", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "WX-037 in combination with WX-554", 
                "intervention_name": "WX-554", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sutton", 
                        "country": "United Kingdom", 
                        "state": "Surrey", 
                        "zip": "SM2 5PT"
                    }, 
                    "name": "Royal Marsden NHS Foundation Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom", 
                        "zip": "G12 0YN"
                    }, 
                    "name": "Beatson West of Scotland Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE1 9RT"
                    }, 
                    "name": "Guy's and St Thomas' Foundation Trust, Guy's Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the PI3K Inhibitor WX-037, Given as a Single Agent and in Combination With the MEK Inhibitor WX-554, in Patients With Solid Tumors", 
        "overall_official": {
            "affiliation": "Royal Marsden NHS Foundation Trust", 
            "last_name": "Udai Banerji, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of Dose limiting toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "during cycle 1 (21days) of treatment with WX-037"
            }, 
            {
                "measure": "Incidence of Dose Limiting toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "during cycle 1 (21 days) of treatment with WX-037 and WX-554"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01859351"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of patients with adverse Events and serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "from cycle 1 day 1 until treatment discontinuation, an estimated average of 18 weeks"
            }, 
            {
                "measure": "Assessment of PK variables, peak plasma concentration (Cmax), area under the curve (AUC)", 
                "safety_issue": "Yes", 
                "time_frame": "two PK profiles in cycle 1"
            }, 
            {
                "measure": "Determination of PD markers; changes from baseline in biomarkers of pathway inhibition", 
                "safety_issue": "Yes", 
                "time_frame": "predose until treatment discontinuation, an estimated average of 18 weeks"
            }
        ], 
        "source": "Wilex", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wilex", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014", 
        "why_stopped": "Study terminated for business reasons"
    }
}